Webinar | How Eligibility Review Can Enhance Clinical Trial Outcomes
Join our experts as they discuss their strategies to help sites identify suitable subjects, protect study investment and obtain clearer results.
Clinical trials have a high failure rate, even for those compounds that have demonstrated efficacy in Phase 2 in the target population. CNS trials are associated with some of the highest failure rates and pose unique challenges. Clinical trials in CNS/Neuroscience are complex and prone to producing uninterpretable or ambiguous results.
This can have grave effects on the development of potentially effective treatments- leading to program delay or cancellation, as well as company failure. Measures that help to increase the likelihood of a clear, interpretable signal, and avoid unnecessary trial failure are therefore of great potential value.
The enrollment of unsuitable subjects has the potential to have a significant financial cost to sponsors as well as risk signal detection.
Watch the webinar below to learn how to help sites identify suitable subjects, minimize noise, protect study investment and help obtain clearer results.
If you are interested in speaking to our experts, please contact:
Talar Hopyan, Ph.D., C.Psych, Global Head, Clinical Surveillance & Training (CST), Medical & Scientific Management
[email protected]
Beth Eisenberg, PhD, Scientific Director, Clinical Surveillance & Training (CST), Medical and Scientific Management
[email protected]
Related Content
Looking for exclusive insight?
